Loading…

Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated

Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular and cellular cardiology 2014-09, Vol.74, p.330-339
Main Authors: Gemel, Joanna, Simon, Adria R, Patel, Dakshesh, Xu, Qin, Matiukas, Arvydas, Veenstra, Richard D, Beyer, Eric C
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833
cites cdi_FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833
container_end_page 339
container_issue
container_start_page 330
container_title Journal of molecular and cellular cardiology
container_volume 74
creator Gemel, Joanna
Simon, Adria R
Patel, Dakshesh
Xu, Qin
Matiukas, Arvydas
Veenstra, Richard D
Beyer, Eric C
description Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four different mutants (P88S, G38D, V85I, and L229M) were expressed by the transfection of communication-deficient HeLa cells or HL-1 cardiomyocytes. Biophysical channel properties and the sub-cellular localization and protein levels of Cx40 were characterized. Wild type Cx40 and all mutants except P88S formed gap junction plaques and induced significant gap junctional conductances. The functional mutants showed only modest alterations of single channel conductances or gating by trans-junctional voltage as compared to wtCx40. However, immunoblotting indicated that the steady state levels of G38D, V85I, and L229M were reduced relative to wtCx40; most strikingly, G38D was only 20–31% of wild type levels. After the inhibition of protein synthesis with cycloheximide, G38D (and to a lesser extent the other mutants) disappeared much faster than wtCx40. Treatment with the proteasomal inhibitor, epoxomicin, greatly increased levels of G38D and restored the abundance of gap junctions and the extent of intercellular dye transfer. Thus, G38D, V85I, and L229M are functional mutants of Cx40 with small alterations of physiological properties, but accelerated degradation by the proteasome. These findings suggest a novel mechanism (protein instability) for the pathogenesis of AF due to a connexin mutation and a novel approach to therapy (protease inhibition).
doi_str_mv 10.1016/j.yjmcc.2014.06.010
format article
fullrecord <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4135452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022282814002041</els_id><sourcerecordid>S0022282814002041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833</originalsourceid><addsrcrecordid>eNqFkcFuFDEMhiNERZfCEyCheYGZOplkkjlQCRUoSJV6aDlHWY9TMp3NVJls1X17smypgAsHy5bs_7f8mbF3HBoOvDsdm924QWwEcNlA1wCHF2zFoVe1UUa-ZCsAIWphhDlmr5dlBIBetu0rdixkr9sSK3b1iW6TG1wOc6xmX7kK5xjpMUQJ1WabXczVFOIdDVWeK5dTcFPlwzqFaTqIwlI5RJoouUzDG3bk3bTQ26d8wr5_-Xxz_rW-vLr4dv7xskbFZa4Hg0a2RnkjNHmvO-W1cSi8MLrz2rtedbjue9StBr3GjgbsnPRKkgNl2vaEnR1877frTWlSzMlN9j6FjUs7O7tg_-7E8MPezg9W8lZJJYpBezDANC9LIv-s5WD3fO1of_G1e74WOlv4FtX7P9c-a34DLQMfDgNUjn8IlOyCgSLSEBJhtsMc_rPg7B89FvwB3XRHO1rGeZti4Wq5XYQFe71_8f7DXJYKynE_AaQOo-I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated</title><source>ScienceDirect Journals</source><creator>Gemel, Joanna ; Simon, Adria R ; Patel, Dakshesh ; Xu, Qin ; Matiukas, Arvydas ; Veenstra, Richard D ; Beyer, Eric C</creator><creatorcontrib>Gemel, Joanna ; Simon, Adria R ; Patel, Dakshesh ; Xu, Qin ; Matiukas, Arvydas ; Veenstra, Richard D ; Beyer, Eric C</creatorcontrib><description>Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four different mutants (P88S, G38D, V85I, and L229M) were expressed by the transfection of communication-deficient HeLa cells or HL-1 cardiomyocytes. Biophysical channel properties and the sub-cellular localization and protein levels of Cx40 were characterized. Wild type Cx40 and all mutants except P88S formed gap junction plaques and induced significant gap junctional conductances. The functional mutants showed only modest alterations of single channel conductances or gating by trans-junctional voltage as compared to wtCx40. However, immunoblotting indicated that the steady state levels of G38D, V85I, and L229M were reduced relative to wtCx40; most strikingly, G38D was only 20–31% of wild type levels. After the inhibition of protein synthesis with cycloheximide, G38D (and to a lesser extent the other mutants) disappeared much faster than wtCx40. Treatment with the proteasomal inhibitor, epoxomicin, greatly increased levels of G38D and restored the abundance of gap junctions and the extent of intercellular dye transfer. Thus, G38D, V85I, and L229M are functional mutants of Cx40 with small alterations of physiological properties, but accelerated degradation by the proteasome. These findings suggest a novel mechanism (protein instability) for the pathogenesis of AF due to a connexin mutation and a novel approach to therapy (protease inhibition).</description><identifier>ISSN: 0022-2828</identifier><identifier>EISSN: 1095-8584</identifier><identifier>DOI: 10.1016/j.yjmcc.2014.06.010</identifier><identifier>PMID: 24973497</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Action Potentials - drug effects ; Animals ; Atrial fibrillation ; Atrial Fibrillation - genetics ; Atrial Fibrillation - metabolism ; Atrial Fibrillation - pathology ; Cardiovascular ; Cell Line, Tumor ; Connexin40 ; Connexins - genetics ; Connexins - metabolism ; Cycloheximide - pharmacology ; Gap Junction alpha-5 Protein ; Gap junctions ; Gap Junctions - drug effects ; Gap Junctions - metabolism ; Gene Expression Regulation ; Heart Atria - drug effects ; Heart Atria - metabolism ; Heart Atria - pathology ; Humans ; Ion channels ; Mice ; Mutation ; Myocytes, Cardiac - drug effects ; Myocytes, Cardiac - metabolism ; Myocytes, Cardiac - pathology ; Oligopeptides - pharmacology ; Patch-Clamp Techniques ; Proteasome ; Proteasome Endopeptidase Complex - drug effects ; Proteasome Endopeptidase Complex - metabolism ; Proteasome Inhibitors - pharmacology ; Protein degradation ; Protein Stability ; Protein Synthesis Inhibitors - pharmacology ; Proteolysis ; Signal Transduction ; Transgenes ; Ubiquitination</subject><ispartof>Journal of molecular and cellular cardiology, 2014-09, Vol.74, p.330-339</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><rights>2014 Elsevier Ltd. All rights reserved. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833</citedby><cites>FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833</cites><orcidid>0000-0001-8044-1356</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24973497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gemel, Joanna</creatorcontrib><creatorcontrib>Simon, Adria R</creatorcontrib><creatorcontrib>Patel, Dakshesh</creatorcontrib><creatorcontrib>Xu, Qin</creatorcontrib><creatorcontrib>Matiukas, Arvydas</creatorcontrib><creatorcontrib>Veenstra, Richard D</creatorcontrib><creatorcontrib>Beyer, Eric C</creatorcontrib><title>Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated</title><title>Journal of molecular and cellular cardiology</title><addtitle>J Mol Cell Cardiol</addtitle><description>Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four different mutants (P88S, G38D, V85I, and L229M) were expressed by the transfection of communication-deficient HeLa cells or HL-1 cardiomyocytes. Biophysical channel properties and the sub-cellular localization and protein levels of Cx40 were characterized. Wild type Cx40 and all mutants except P88S formed gap junction plaques and induced significant gap junctional conductances. The functional mutants showed only modest alterations of single channel conductances or gating by trans-junctional voltage as compared to wtCx40. However, immunoblotting indicated that the steady state levels of G38D, V85I, and L229M were reduced relative to wtCx40; most strikingly, G38D was only 20–31% of wild type levels. After the inhibition of protein synthesis with cycloheximide, G38D (and to a lesser extent the other mutants) disappeared much faster than wtCx40. Treatment with the proteasomal inhibitor, epoxomicin, greatly increased levels of G38D and restored the abundance of gap junctions and the extent of intercellular dye transfer. Thus, G38D, V85I, and L229M are functional mutants of Cx40 with small alterations of physiological properties, but accelerated degradation by the proteasome. These findings suggest a novel mechanism (protein instability) for the pathogenesis of AF due to a connexin mutation and a novel approach to therapy (protease inhibition).</description><subject>Action Potentials - drug effects</subject><subject>Animals</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - genetics</subject><subject>Atrial Fibrillation - metabolism</subject><subject>Atrial Fibrillation - pathology</subject><subject>Cardiovascular</subject><subject>Cell Line, Tumor</subject><subject>Connexin40</subject><subject>Connexins - genetics</subject><subject>Connexins - metabolism</subject><subject>Cycloheximide - pharmacology</subject><subject>Gap Junction alpha-5 Protein</subject><subject>Gap junctions</subject><subject>Gap Junctions - drug effects</subject><subject>Gap Junctions - metabolism</subject><subject>Gene Expression Regulation</subject><subject>Heart Atria - drug effects</subject><subject>Heart Atria - metabolism</subject><subject>Heart Atria - pathology</subject><subject>Humans</subject><subject>Ion channels</subject><subject>Mice</subject><subject>Mutation</subject><subject>Myocytes, Cardiac - drug effects</subject><subject>Myocytes, Cardiac - metabolism</subject><subject>Myocytes, Cardiac - pathology</subject><subject>Oligopeptides - pharmacology</subject><subject>Patch-Clamp Techniques</subject><subject>Proteasome</subject><subject>Proteasome Endopeptidase Complex - drug effects</subject><subject>Proteasome Endopeptidase Complex - metabolism</subject><subject>Proteasome Inhibitors - pharmacology</subject><subject>Protein degradation</subject><subject>Protein Stability</subject><subject>Protein Synthesis Inhibitors - pharmacology</subject><subject>Proteolysis</subject><subject>Signal Transduction</subject><subject>Transgenes</subject><subject>Ubiquitination</subject><issn>0022-2828</issn><issn>1095-8584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqFkcFuFDEMhiNERZfCEyCheYGZOplkkjlQCRUoSJV6aDlHWY9TMp3NVJls1X17smypgAsHy5bs_7f8mbF3HBoOvDsdm924QWwEcNlA1wCHF2zFoVe1UUa-ZCsAIWphhDlmr5dlBIBetu0rdixkr9sSK3b1iW6TG1wOc6xmX7kK5xjpMUQJ1WabXczVFOIdDVWeK5dTcFPlwzqFaTqIwlI5RJoouUzDG3bk3bTQ26d8wr5_-Xxz_rW-vLr4dv7xskbFZa4Hg0a2RnkjNHmvO-W1cSi8MLrz2rtedbjue9StBr3GjgbsnPRKkgNl2vaEnR1877frTWlSzMlN9j6FjUs7O7tg_-7E8MPezg9W8lZJJYpBezDANC9LIv-s5WD3fO1of_G1e74WOlv4FtX7P9c-a34DLQMfDgNUjn8IlOyCgSLSEBJhtsMc_rPg7B89FvwB3XRHO1rGeZti4Wq5XYQFe71_8f7DXJYKynE_AaQOo-I</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Gemel, Joanna</creator><creator>Simon, Adria R</creator><creator>Patel, Dakshesh</creator><creator>Xu, Qin</creator><creator>Matiukas, Arvydas</creator><creator>Veenstra, Richard D</creator><creator>Beyer, Eric C</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8044-1356</orcidid></search><sort><creationdate>20140901</creationdate><title>Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated</title><author>Gemel, Joanna ; Simon, Adria R ; Patel, Dakshesh ; Xu, Qin ; Matiukas, Arvydas ; Veenstra, Richard D ; Beyer, Eric C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Action Potentials - drug effects</topic><topic>Animals</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - genetics</topic><topic>Atrial Fibrillation - metabolism</topic><topic>Atrial Fibrillation - pathology</topic><topic>Cardiovascular</topic><topic>Cell Line, Tumor</topic><topic>Connexin40</topic><topic>Connexins - genetics</topic><topic>Connexins - metabolism</topic><topic>Cycloheximide - pharmacology</topic><topic>Gap Junction alpha-5 Protein</topic><topic>Gap junctions</topic><topic>Gap Junctions - drug effects</topic><topic>Gap Junctions - metabolism</topic><topic>Gene Expression Regulation</topic><topic>Heart Atria - drug effects</topic><topic>Heart Atria - metabolism</topic><topic>Heart Atria - pathology</topic><topic>Humans</topic><topic>Ion channels</topic><topic>Mice</topic><topic>Mutation</topic><topic>Myocytes, Cardiac - drug effects</topic><topic>Myocytes, Cardiac - metabolism</topic><topic>Myocytes, Cardiac - pathology</topic><topic>Oligopeptides - pharmacology</topic><topic>Patch-Clamp Techniques</topic><topic>Proteasome</topic><topic>Proteasome Endopeptidase Complex - drug effects</topic><topic>Proteasome Endopeptidase Complex - metabolism</topic><topic>Proteasome Inhibitors - pharmacology</topic><topic>Protein degradation</topic><topic>Protein Stability</topic><topic>Protein Synthesis Inhibitors - pharmacology</topic><topic>Proteolysis</topic><topic>Signal Transduction</topic><topic>Transgenes</topic><topic>Ubiquitination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gemel, Joanna</creatorcontrib><creatorcontrib>Simon, Adria R</creatorcontrib><creatorcontrib>Patel, Dakshesh</creatorcontrib><creatorcontrib>Xu, Qin</creatorcontrib><creatorcontrib>Matiukas, Arvydas</creatorcontrib><creatorcontrib>Veenstra, Richard D</creatorcontrib><creatorcontrib>Beyer, Eric C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of molecular and cellular cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gemel, Joanna</au><au>Simon, Adria R</au><au>Patel, Dakshesh</au><au>Xu, Qin</au><au>Matiukas, Arvydas</au><au>Veenstra, Richard D</au><au>Beyer, Eric C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated</atitle><jtitle>Journal of molecular and cellular cardiology</jtitle><addtitle>J Mol Cell Cardiol</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>74</volume><spage>330</spage><epage>339</epage><pages>330-339</pages><issn>0022-2828</issn><eissn>1095-8584</eissn><abstract>Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four different mutants (P88S, G38D, V85I, and L229M) were expressed by the transfection of communication-deficient HeLa cells or HL-1 cardiomyocytes. Biophysical channel properties and the sub-cellular localization and protein levels of Cx40 were characterized. Wild type Cx40 and all mutants except P88S formed gap junction plaques and induced significant gap junctional conductances. The functional mutants showed only modest alterations of single channel conductances or gating by trans-junctional voltage as compared to wtCx40. However, immunoblotting indicated that the steady state levels of G38D, V85I, and L229M were reduced relative to wtCx40; most strikingly, G38D was only 20–31% of wild type levels. After the inhibition of protein synthesis with cycloheximide, G38D (and to a lesser extent the other mutants) disappeared much faster than wtCx40. Treatment with the proteasomal inhibitor, epoxomicin, greatly increased levels of G38D and restored the abundance of gap junctions and the extent of intercellular dye transfer. Thus, G38D, V85I, and L229M are functional mutants of Cx40 with small alterations of physiological properties, but accelerated degradation by the proteasome. These findings suggest a novel mechanism (protein instability) for the pathogenesis of AF due to a connexin mutation and a novel approach to therapy (protease inhibition).</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24973497</pmid><doi>10.1016/j.yjmcc.2014.06.010</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8044-1356</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2828
ispartof Journal of molecular and cellular cardiology, 2014-09, Vol.74, p.330-339
issn 0022-2828
1095-8584
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4135452
source ScienceDirect Journals
subjects Action Potentials - drug effects
Animals
Atrial fibrillation
Atrial Fibrillation - genetics
Atrial Fibrillation - metabolism
Atrial Fibrillation - pathology
Cardiovascular
Cell Line, Tumor
Connexin40
Connexins - genetics
Connexins - metabolism
Cycloheximide - pharmacology
Gap Junction alpha-5 Protein
Gap junctions
Gap Junctions - drug effects
Gap Junctions - metabolism
Gene Expression Regulation
Heart Atria - drug effects
Heart Atria - metabolism
Heart Atria - pathology
Humans
Ion channels
Mice
Mutation
Myocytes, Cardiac - drug effects
Myocytes, Cardiac - metabolism
Myocytes, Cardiac - pathology
Oligopeptides - pharmacology
Patch-Clamp Techniques
Proteasome
Proteasome Endopeptidase Complex - drug effects
Proteasome Endopeptidase Complex - metabolism
Proteasome Inhibitors - pharmacology
Protein degradation
Protein Stability
Protein Synthesis Inhibitors - pharmacology
Proteolysis
Signal Transduction
Transgenes
Ubiquitination
title Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Degradation%20of%20a%20connexin40%20mutant%20linked%20to%20atrial%20fibrillation%20is%20accelerated&rft.jtitle=Journal%20of%20molecular%20and%20cellular%20cardiology&rft.au=Gemel,%20Joanna&rft.date=2014-09-01&rft.volume=74&rft.spage=330&rft.epage=339&rft.pages=330-339&rft.issn=0022-2828&rft.eissn=1095-8584&rft_id=info:doi/10.1016/j.yjmcc.2014.06.010&rft_dat=%3Celsevier_pubme%3ES0022282814002041%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24973497&rfr_iscdi=true